NASDAQ:MGTXMeiraGTx Stock Price, Forecast & News

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MGTX shares have increased by 12.6% and is now trading at $15.87. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MeiraGTx.

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MeiraGTx.

MeiraGTx Holdings PLC (NASDAQ:MGTX) issued its earnings results on Thursday, May, 7th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. The firm earned $4.21 million during the quarter. MeiraGTx had a negative return on equity of 29.96% and a negative net margin of 313.70%. View MeiraGTx's earnings history.

2 analysts have issued 1-year target prices for MeiraGTx's shares. Their forecasts range from $40.00 to $45.00. On average, they expect MeiraGTx's share price to reach $42.50 in the next year. This suggests a possible upside of 167.8% from the stock's current price. View analysts' price targets for MeiraGTx.

Media headlines about MGTX stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MeiraGTx earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutMeiraGTx.

MeiraGTx saw a decline in short interest in May. As of May 15th, there was short interest totaling 579,000 shares, a decline of 7.5% from the April 30th total of 626,000 shares. Based on an average daily volume of 114,000 shares, the short-interest ratio is currently 5.1 days. Approximately 2.0% of the shares of the stock are sold short. View MeiraGTx's Current Options Chain.

Some companies that are related to MeiraGTx include Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST), Cortexyme (CRTX), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), I-Mab (BDTX), Mesoblast (MESO), Beam Therapeutics (BEAM), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG) and Passage Bio (PASG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), InVitae (NVTA), Sorrento Therapeutics (SRNE) and Canopy Growth (CGC).

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

MeiraGTx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (9.59%), Johnson & Johnson Innovation JJDC Inc. (7.76%), BlackRock Inc. (3.29%), Prosight Management LP (1.52%), State Street Corp (0.96%) and Alyeska Investment Group L.P. (0.93%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk. View institutional ownership trends for MeiraGTx.

MGTX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, Ensign Peak Advisors Inc, Victory Capital Management Inc., Victory Capital Management Inc., and SG Americas Securities LLC. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk. View insider buying and selling activity for MeiraGTx.

MGTX stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson Innovation JJDC Inc., Orbimed Advisors LLC, Alps Advisors Inc., Rhenman & Partners Asset Management AB, Prosight Management LP, JPMorgan Chase & Co., Fort Sheridan Advisors LLC, and AQR Capital Management LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman. View insider buying and selling activity for MeiraGTx.

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGTX stock can currently be purchased for approximately $15.87.

MeiraGTx has a market capitalization of $592.93 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.

The official website for MeiraGTx is www.meiragtx.com.

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]